The Nobuto Yamamoto Papers

Older works:

His work dates back to at least 1957. The 1961 article gives a 'current' address at The Institute for Cancer Research, Philadelphia. Dr. Nobuto Yamamoto has been researching cancer a long time.

Here is a listing of some of his papers, starting with the oldest at the top.

PHOTODYNAMIC INACTIVATION OF BACTERIOPHAGE AND ITS INHIBITION 1958.

Effect of Egg Passage on the Reaction Between HVJ (Hemagglutinating Virus of Japan) and Chicken Erythrocytes Toshisada Matsumoto, Nobuto Yamamoto and Koichiro Maeno The Journal of Immunology, 1961, 87: 590-598.

Genetic Evolution of Bacteriophage, II. Physical Length of the Homologous Region in a Hybrid between Serologically and Morphologically Unrelated Phages by Hiroto Akiyoshi and Nobuto Yamamoto. 1970.

From Thomas Foxen Anderson tribute. "In his new lab at the ICR, Tom (Thomas Foxen Anderson) was using his state-of-the-art Siemens microscope to investigate the fine structures of phages. In one study, carried out with Nobuto Yamamoto, a young research associate from Japan, an inter-esting phenomenon termed “genomic masking” was discovered. These studies involved a temperate phage that infects the bacterium Salmonella typhimurium. At a low frequency,bacteria infected with phage P22 produced, in addition to the P22 progeny, a variant form with a morphologically distinct tail structure. It turned out that the variant was the result of an exchange between a latent capsid-encoding gene in the bacterial genome and the normal capsid gene of the infecting phage. This observation was one of the earliest examples of such genetic exchange."

Genetic studies of hybrids between coliphage λ and Salmonella phage P22: Genetic analysis of the P22-λ hybrid class 1977. .Nobuto Yamamoto, N. Ushijima, P. Gemski and L. S. Baron

You can get many more papers from this productive scientist at http://www.springerlink.com/content/?k=nobuto+yamamoto

*** let's skip ahead to more recent related work ***

Ngwenya, BZ and Yamamoto, N. 1985. Activation of peritoneal macrophages by lysophos-phatidylcholine. Biochim. Biophys. Acta 839: 9–15. | PubMed | ChemPort |

Ngwenya, BZ and Yamamoto, N. 1986. Effects of inflammation products on immune systems: Lysophosphatidylcholine stimulates macrophages. Cancer Immunol. Immunother. 21: 1074–1082. PubMed

Yamamoto, N and Ngwenya, BZ. 1987. Activation of macrophages by lysophospholipids and ether derivatives of neutral lipids and phospholipids. Cancer Res. 47: 2008–2013. | PubMed | ChemPort |

Yamamoto, N St, Claire, DA, Homma, S and Ngwenya, BZ. 1988. Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res. 48: 6044–6049. | PubMed | ChemPort |

Ngwenya, BZ and Yamamoto, N. 1990. Contribution of lysophosphatidylcholine-treated nonadherent cells to mechanism of macrophage activation. Proc. Soc. Exp. Biol. Med. 193: 118–124. | PubMed | ChemPort |

Homma, S and Yamamoto, N. 1990. Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin. Exp. Immunol. 79: 307–313. | PubMed | ChemPort |

Homma, S, Millman, I and Yamamoto, N. 1990. Serum factor for macrophage activation after IM vitro dodecylglycerol treatment of mouse lymphocytes. Immunol. Cell Biol. 68: 137–142.

Yamamoto, N, Homma, S and Millman, I. 1991. Identification of the serum factor required for in vitro activation of macrophages: Role of vitamin D3 binding protein (Group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J. Immunol. 147: 273–280. | PubMed | ChemPort |

Yamamoto, N, Homma, S, Haddad, JG and Kowalski, MN. 1991. Vitamin D3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells. Immunology 74: 420–424. | PubMed | ChemPort | Full text

Yamamoto, N and Homma, S. 1991. Vitamin D3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal Factor from lysophosphatidylcholine-treated lymphocytes. Proc. Natl Acad. Sci. USA. 88: 8539–8543. | Article | PubMed | ChemPort |

Effects of Vitamin D3-Binding Protein-Derived Macrophage Activating Factor (GcMAF) on Angiogenesis. (full pdf) Shigeru Kanda, Yasushi Mochizuki, Yasuyoshi Miyata, Hiroshi Kanetake, Nobuto Yamamoto. Journal of the National Cancer Institute, Vol. 94, No. 17, 1311-1319, September 4, 2002 "Conclusions: In addition to its ability to activate tumoricidal macrophages, GcMAF has direct antiangiogenic effects on endothelial cells independent of tissue origin. The antiangiogenic effects of GcMAF may be mediated through the CD36 receptor."

Vitamin D-binding protein (group-specific component) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. 1993. Homma S. (1) ; Yamamoto M. ; Yamamoto N. ; Abstract: In vitro treatment of mouse peritoneal cells with 1 g lysophosphatidylcholine (lyso–Pc)/mL in serum free-0.1% egg albumin-supplemented RPMI 1640 medium for 30 min, followed by 3 h cultivation in a medium supplemented with human serum, resulted in a greatly enhanced Fc-receptor-mediated phagocytic activity of macrophages. Vitamin D-binding protein (group-specific component [Gc]) of 2-globulin fraction was shown to he the sole serum glycoprotein required for the generation of a potent macrophage-activating factor. When a mixture of lysophosphatidylcholine (lyso-Pc)-treated nonadherent and adherent cells were cultured in a medium supplemented with a small amount of purified Gc protein (1 ng/mL), a greatly enhanced activation of macrophages was demonstrated. The generation of macrophage-activating factor from purified Gc protein was far more efficient than that from whole serum, indicating that a serum component is inhibitory to the activation process of macrophages. While three other major serum glycoproteins (2-macrcglobulin, 2-HS-glycoprotein and haptoglobin) were neither stimulatory nor inhibitory to lyso-Pc-primed macrophage activation, serum albumin (competitively with Gc protein) appeared to be inhibitory to the process of macrophage activation.

Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta- galactosidase of B cells and sialidase of T cells 1993. N Yamamoto and R Kumashiro

Deglycosylation of Serum Vitamin D3-binding Protein Leads to Immunosuppression in Cancer Patients (full pdf) Nobuto Yamamoto, Venkateswara R. Naraparaju, and Sucha O. Asbell
Cancer Res 1996 56: 2827-2831.

Adenovirus-mediated Gene Transduction of IkB or IkB Plus Bax Gene Drastically Enhances Tumor Necrosis Factor (TNF)-induced Apoptosis in Human Gliomas. Cancer Science
Volume 91 Issue 1 Page 41-51, January 2000

top